CAL 101 - Calluna Pharma
Alternative Names: CAL-101 - Calluna PharmaLatest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Calluna Pharma
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
- Mechanism of Action S100 calcium-binding protein A4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fibrosis; Inflammation; Plaque psoriasis
Most Recent Events
- 18 Dec 2024 Calluna Pharma plans a phase II trial for Inflammation and Fibrosis in first half of 2025 (Calluna Pipeline, December 2024)
- 24 Oct 2024 Pharmacokinetics and adverse events data from a Phase I trial in Plaque psoriasis released by Calluna Pharma
- 24 Oct 2024 Calluna Pharma completes a phase-I clinical trials in Plaque psoriasis in United Kingdom (Parenteral)